{"version":"1.0","type":"rich","provider_name":"NULLPEN","provider_url":"https://nullpen.com","title":"Trial results posted: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","cache_age":300,"width":400,"height":320,"html":"<iframe src=\"https://nullpen.com/embed?story=sha256%3Ab6f309f631160bdbd3782751dcb6ef393d64190752bf229e3314acbb905b126b\" title=\"Trial results posted: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)\" width=\"400\" height=\"320\" loading=\"lazy\" style=\"border:0;max-width:100%\" referrerpolicy=\"strict-origin-when-cross-origin\" sandbox=\"allow-popups allow-popups-to-escape-sandbox\"></iframe>"}